Envoy Medical, Inc. Class A COCH 深 沪
已收盘 05-22 16:00:00 美东时间
0.709
-0.024
-3.26%
华盛通- 最 高0.73
- 今 开0.725
- 成交量 7.25万股
- 最 低 0.7002
- 昨 收 0.7329
- 总市值 5.45万
- 52周最高 1.89
- 市盈率 静 --
- 换手率 0.09%
- 52周最低 0.3625
- 委 比 87.13%
- 总股本 7.69万
- 历史最高 11.72
- 量 比 0.44
- 振 幅 4.07%
- 历史最低 0.00
- 每 手 1
- 风险率 0.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Envoy Medical Secures Multiple Australia And Europe Patents For Implantable Hearing System Innovations And Battery Recharge Safety Technology
ustralian and European Patent Offices Grant the Company Four Patents Relating to Key Innovations in Implantable System Design, Signal Analysis, and Battery Recharge SafetyWhite Bear Lake, Minnesota--(Newsfile Corp. - May
05-20 20:39
Envoy Medical Q1 EPS $(0.08) Beats $(0.14) Estimate, Sales $39.000K Miss $60.000K Estimate
Envoy Medical (NASDAQ:COCH) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.14) by 42.86 percent. This is a 72.41 percent increase over losses of $(0.29) per share from the
05-11 20:13
Envoy Medical Achieves Full Enrollment Of U.S. Pivotal Clinical Study To Evaluate Fully Implanted Cochlear Implant Seeking FDA Nod
Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today reported first quarter 2026 results and landmark achievements that
05-11 20:10
Envoy Medical Announces First Podium Presentations Of Clinical Data From First Stage Of Pivotal Clinical Study Of Investigational Acclaim Cochlear Implant, Fully Implanted Cochlear Implant System
Positive Initial 6-Month Data from First 10 Patients and Improvements in Speech Understanding and Quality of Life Scores Presented; Additional Presentations Scheduled in Early MayDetails to be Discussed During Fireside
04-28 20:38
美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
HC Wainwright & Co. Initiates Coverage On Envoy Medical with Buy Rating, Announces Price Target of $2.5
HC Wainwright & Co. analyst Yi Chen initiates coverage on Envoy Medical (NASDAQ:COCH) with a Buy rating and announces Price Target of $2.5.
03-31 19:04
Envoy Medical Q4 EPS $(0.26) Beats $(0.30) Estimate, Sales $75.000K Beat $70.000K Estimate
Envoy Medical (NASDAQ:COCH) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.30) by 13.33 percent. This is a 43.48 percent increase over losses of $(0.46) per share from the
03-23 20:54
EXCLUSIVE: Envoy Medical Hits Trial Milestone For Cochlear Implant Designed To Work With Natural Ear
Envoy Medical completes enrollment for its Acclaim cochlear implant trial, a fully implanted device designed without external components.
03-11 19:46
Envoy Medical regains compliance with Nasdaq
Envoy Medical (NASDAQ:COCH) announced on Tuesday that Nasdaq notified the company it had regained compliance with Listing Rule 5550(b)(2) under alternatives permitted by Rule 5550(b). The company said...
02-24 21:40
Envoy Medical Issues Update Highlighting Recent Financing, Noting Further Positive Clinical Trial Progress, And Announcing Upcoming Fireside Chat
Financing was led by new investor and top-tier healthcare fund Nantahala Capital and longtime Envoy Medical shareholder, billionaire Glen TaylorClosing of $30 million in gross proceeds in upsized offering, with up to an
02-19 21:07
